Score Overview
Explore the 2021 public Archive ranking →
Where Sonoma Pharmaceuticals Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- SNOA
2017: 44.1% · 2021: 64.4% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-23 | $ 1.11 | — |
1 Year2025-10-23 | $ 3.68 | -69.84% |
5 Years2021-10-22 | $ 111.40 | -99.00% |
10 Years2016-10-21 | $ 720.00 | -99.85% |
All Time2007-01-25 | $ 49.14K | -100.00% |
| Period | Last Price2026-10-23 | 1 Year2025-10-23 | 5 Years2021-10-22 | 10 Years2016-10-21 | All Time2007-01-25 |
|---|---|---|---|---|---|
| Price | $ 1.11 | $ 3.68 | $ 111.40 | $ 720.00 | $ 49.14K |
| Return | — | -69.84% | -99.00% | -99.85% | -100.00% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 21M | -$ 2M | $ 5M |
| 2026 | $ 19M | -$ 3M | $ 2M |
| 2025 | $ 14M | -$ 3M | $ 5M |
| 2024 | $ 12M | -$ 4M | $ 3M |
| 2023 | $ 13M | -$ 5M | $ 3M |
| 2022 | $ 12M | -$ 5M | $ 7M |
| 2021 | $ 18M | -$ 3M | $ 4M |
| 2020 | $ 17M | -$ 3M | $ 3M |
| 2019 | $ 18M | -$ 11M | $ 3M |
| 2018 | $ 16M | -$ 14M | $ 10M |
| 2017 | $ 12M | $ 9M | $ 17M |
| 2016 | $ 9M | -$ 10M | $ 7M |
| 2015 | $ 13M | -$ 8M | $ 6M |
| 2014 | $ 13M | $ 3M | $ 5M |
| 2013 | $ 15M | -$ 5M | $ 7M |
| 2012 | $ 12M | -$ 7M | $ 3M |
| 2011 | $ 9M | -$ 7M | $ 4M |
| 2010 | $ 7M | -$ 8M | $ 6M |
| 2009 | $ 5M | -$ 17M | $ 1M |
| 2008 | $ 3M | -$ 20M | $ 18M |
| IPO2007 | $ 4M | -$ 19M | $ 19M |
Sonoma Pharmaceuticals Inc fundamental performance
Between 2021 and 2026, revenue grew from $ 18M to $ 19M and net income went from -$ 3M to -$ 3M. Revenue increased in 4 of those 5 years; net income in 4.
Across Sonoma Pharmaceuticals Inc's full reported history, from 2007 to 2026, revenue grew from $ 4M to $ 19M and net income went from -$ 19M to -$ 3M. Revenue increased in 70% of the years measured; net income in 65%.
Sonoma Pharmaceuticals Inc currently holds a 5-year HDB Score of 6.9 out of 10. How the HDB Score is calculated.
Membership
Continue SNOA’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,112 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
